IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates ...

Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...

The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has ...

Gilead Sciences has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio. The Suzhou-based biotech ...

ISM2196 is a novel, potent WRN inhibitor, designed with the assistance of Alchemistry, one of the latest modules of Chemistry 42. CAMBRIDGE, Mass., September 11, 2024--- Insilico Medicine(“Insilico”), ...

GSK plc said in paperwork filed with the U.S. SEC that the potentially whopping deal inked in the summer of 2020 with Ideaya Biosciences Inc. has gone down the tubes. The two firms were collaborating ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($570 ...

Gilead Sciences is stepping deeper into synthetic lethality, licensing a clinic-ready MAT2A (methionine adenosyltransferase 2a) inhibitor from Suzhou, China-based Genhouse Bio Co. Ltd. in a deal worth ...

Figure 1 BET inhibition is synthetic lethal to OXPHOS blockage in liver cancer. Left: GDH1-dependent glutamine metabolic remodeling upon BET inhibition. Right: “Synthetic lethality” targeting OXPHOS ...

BOSTON--(BUSINESS WIRE)--Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small ...